Additional Relevant Details The trial will be a two part Phase 2/3 adaptive design in haemodialysis patients exhibiting moderate-to-severe uremic pruritus. Part a will be randomized, double-blind, placebo controlled study of three doses of I.V. CR845 administered three times a week after dialysis over a period treatment of up to eight weeks. Part b will be randomized, double-blind, placebo controlled study of one optimized dose of I.V. CR845 administered TIW, that's three times a week, over a 12 week treatment period.  The primary endpoint will be reduction in worst itching scores from baseline values.  The study is set to initiate the first half of 2016.